



NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose **ALL** financial relationships they have had in the past **24 months** with ineligible companies. The ACCME *Standards for Integrity and Independence* require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past **24 months** are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of **ALL** financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

NCCN Staff Disclosures

None of the planners for this educational activity have **relevant** financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.



Faculty Disclosures: Congress Planning Committee

The faculty listed below have **no relevant financial relationships** with ineligible companies to disclose.

Michael Seidman, MD

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Gabriela S. Hobbs, MD

Bristol Myers Squibb: Scientific Advisor
Cogent Biosciences: Consulting Fee
GSK: Scientific Advisor
Incyte Corporation: Grant/Research Support; Scientific Advisor
Merck & Co., Inc.: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
PharmaEssentia Corporation: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Equity Interest/Stock Options
Sobi-Swedish Orphan Biovitrum AB: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

Shaji K. Kumar, MD (*Presenting Faculty*)

AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BD Biosciences: Consulting Fee
BioLineRx Ltd.: Consulting Fee
Bristol Myers Squibb: Grant/Research Support; Scientific Advisor
CARsgen Therapeutics Holdings Limited: Grant/Research Support
GSK: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Moderna, Inc.: Consulting Fee
Oricell Therapeutics: Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN (*Presenting Faculty*)

BD: Consulting Fee; Honoraria

Katie Tobon, PharmD, BCOP (*Presenting Faculty*)

AbbVie, Inc.: Honoraria
Bristol Myers Squibb: Honoraria
Curio Science: Honoraria
Lilly: Honoraria

Andrew D. Zelenetz, MD, PhD (*Congress Chair and Moderator*)

AbbVie, Inc.: Consulting Fee
Arvinas, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
Bristol Myers Squibb / Celgene Corporation / Juno Therapeutics, Inc.: Scientific Advisor
Curio Science: Consulting Fee
DAVA Oncology LP: Consulting Fee
Lilly: Consulting Fee
Genentech, Inc. / Roche: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc. (Kite Pharma): Consulting Fee
GSK: Grant/Research Support
Ipsen: Consulting Fee
MEI Pharma Inc.: Consulting Fee
Pharmacyclics: Grant/Research Support



Faculty Disclosures: Presenting Faculty

The faculty listed below have **no relevant financial relationships** with ineligible companies to disclose.

Natalie S. Callander, MD
Jacqueline Dela Peña, PharmD, BCOP
Jeanelle Folbrecht, PhD
Pallavi Kanwar Galera, MD
Jenna Moran, MSN, FNP-BC
Grace H. Pak, PharmD, MHA, BCPS

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.

Jeremy S. Abramson, MD, MMSc
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee
Bristol Myers Squibb: Consulting Fee; Grant/Research Support
Caribou Biosciences, Inc.: Consulting Fee
Cellestis: Grant/Research Support
Lilly: Consulting Fee
Foresight Diagnostics: Consulting Fee
Genentech, Inc.: Consulting Fee
Johnson & Johnson: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Miltenyi Biotec: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Grant/Research Support
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support
SeaGen: Grant/Research Support

C. Babis Andreadis, MD, MSCE
AbbVie, Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Bristol Myers Squibb: Consulting Fee
Genentech, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Incyte Corporation: Consulting Fee
Pharmacyclics: Consulting Fee

Stefan K. Barta, MD, MS
Acrotech Biopharma, Inc.: Consulting Fee; Honoraria
Bristol Myers Squibb: Honoraria
Citius Pharmaceuticals, Inc.: Honoraria
Daiichi-Sankyo Co.: Consulting Fee
Janssen Pharmaceutical Products, LP: Scientific Advisor
Kyowa Kirin Co., Ltd.: Consulting Fee; Grant/Research Support; Honoraria
Ono Pharmaceutical Co., Ltd.: Honoraria
Secura Bio, Inc.: Honoraria
Vittoria Biotherapeutics, Inc.: Grant/Research Support

Matthew J. Cortese, MD, MPH
AbbVie, Inc.: Consulting Fee; Product/Speakers Bureau; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee; Product/Speakers Bureau; Scientific Advisor
Bristol Myers Squibb: Consulting Fee; Honoraria; Scientific Advisor
Genmab A/S: Consulting Fee
Secura Bio, Inc.: Consulting Fee; Scientific Advisor
Synthekine: Consulting Fee; Scientific Advisor



Disclosure Information

Faculty Disclosures: Presenting Faculty

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Marcos J. de Lima, MD

Incyte Corporation: Scientific Advisor
Kite Pharma: Consulting Fee
kurecells: Officer, Director or any other fiduciary role
Miltenyi Biotec: Grant/Research Support
Priothera Ltd.: Scientific Advisor

Amy E. DeZern, MD, MHS

Geron Corporation: Consulting Fee
Keros Therapeutics: Consulting Fee

Beth Faiman, PhD, MSN, APRN-BC, TCTCN, AOCN, FAAN, FAPO

Bristol Myers Squibb: Honoraria
GSK: Honoraria
Janssen Pharmaceutical Products, LP: Honoraria
sanofi-aventis U.S.: Honoraria

Kateryna Fedorov, MD

Amgen Inc.: Non-royalty Payments

Gaurav Goyal, MD

Recordati Rare Diseases Inc.: Consulting Fee
Sobi-Swedish Orphan Biovitrum AB: Scientific Advisor
SeaGen: Scientific Advisor

Tara M. Graff, DO, MS

AbbVie, Inc.: Consulting Fee; Honoraria; Scientific Advisor
ADC Therapeutics: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
BeOne Medicines: Consulting Fee; Honoraria; Scientific Advisor
Bristol Myers Squibb: Consulting Fee
Genentech, Inc.: Consulting Fee; Scientific Advisor
Genmab A/S: Consulting Fee; Honoraria; Scientific Advisor
Incyte Corporation: Consulting Fee; Honoraria; Scientific Advisor
Janssen Pharmaceutical Products, LP: Consulting Fee
Kite Pharma: Consulting Fee
Lilly USA, LLC: Consulting Fee; Honoraria; Scientific Advisor
Pfizer Inc.: Consulting Fee

Malin Hultcrantz, MD, PhD

AbbVie, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Grant/Research Support
Bristol Myers Squibb: Consulting Fee; Grant/Research Support
GSK: Consulting Fee; Grant/Research Support
Johnson & Johnson: Consulting Fee; Grant/Research Support
Pfizer Inc.: Consulting Fee
SpringWorks Therapeutics: Grant/Research Support
The Binding Site: Grant/Research Support



Faculty Disclosures: Presenting Faculty

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Andrew T. Kuykendall, MD

AbbVie, Inc.: Consulting Fee; Honoraria
Agiros, Inc.: Consulting Fee; Honoraria
Blueprint Medicines: Consulting Fee; Grant/Research Support; Honoraria
Bristol Myers Squibb: Grant/Research Support; Honoraria
Cogent Biosciences: Consulting Fee
CTI BioPharma Corp.: Honoraria
Disc Medicine: Consulting Fee; Honoraria
Geron Corporation: Consulting Fee; Grant/Research Support; Honoraria
GSK: Consulting Fee; Grant/Research Support; Honoraria
Imago Biosciences: Honoraria
Incyte Corporation: Honoraria
Janssen Pharmaceutical Products, LP: Grant/Research Support
Kartos Therapeutics, Inc.: Grant/Research Support
Karyopharm Therapeutics: Consulting Fee; Honoraria
MorphoSys AG: Consulting Fee; Grant/Research Support; Honoraria
Novartis Pharmaceuticals Corporation: Consulting Fee; Grant/Research Support; Honoraria
Opna Biosciences: Consulting Fee; Honoraria
PharmaEssentia Corporation: Consulting Fee; Honoraria
Protagonist Therapeutics Inc.: Consulting Fee; Grant/Research Support; Honoraria; Product/Speakers Bureau
Silence Therapeutics: Consulting Fee; Honoraria
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Honoraria

Carissa Laudati, MSN, FNP-BC, OCN

AbbVie, Inc.: Consulting Fee

Kathy Mooney, MSN, RN, ACNS-BC, TCTCN, OCN

Autolus Therapeutics: Consulting Fee
IOVANCE Biotherapeutics, Inc.: Consulting Fee
Janssen Pharmaceutical Products, LP: Consulting Fee
Kite Pharma: Consulting Fee; Product/Speakers Bureau
KORU Medical Systems: Consulting Fee

Sunita D. Nasta, MD

Caribou Biosciences, Inc.: Grant/Research Support
Deciphera Pharmaceuticals, LLC.: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
Lilly: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support
Pierre Fabre Laboratories: Grant/Research Support
Roche Laboratories, Inc.: Grant/Research Support

Vivian G. Oehler, MD

Novartis Pharmaceuticals Corporation: Consulting Fee
Terns Pharmaceuticals, Inc.: Consulting Fee
Pfizer Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Olalekan Oluwole, MBBS, MPH

AbbVie, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Janssen Pharmaceutical Products, LP: Consulting Fee
Kite Pharma: Grant/Research Support
Nektar Therapeutics: Consulting Fee
Pfizer Inc.: Consulting Fee



Disclosure Information

Faculty Disclosures: Presenting Faculty

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Lindsay Rein, MD

Blueprint Medicines: Consulting Fee; Grant/Research Support
Cogent Biosciences, Inc.: Consulting Fee; Grant/Research Support
Disc Medicine: Grant/Research Support
Geron Corporation: Grant/Research Support
Incyte Corporation: Consulting Fee; Grant/Research Support
Kartos Therapeutics, Inc.: Grant/Research Support
Karyopharm Therapeutics: Grant/Research Support
Kumquat Biosciences Inc.: Grant/Research Support
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee; Grant/Research Support
PharmaEssentia Corporation: Consulting Fee; Grant/Research Support
Protagonist Therapeutics Inc.: Consulting Fee; Grant/Research Support
Silence Therapeutics: Grant/Research Support
Sobi-Swedish Orphan Biovitrum AB: Consulting Fee
Sumitomo Corporation: Consulting Fee; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Grant/Research Support
Telios Pharma, Inc.: Grant/Research Support

Peter A. Riedell, MD

AbbVie, Inc.: Consulting Fee; Grant/Research Support; Honoraria
ADC Therapeutics: Consulting Fee
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Bristol Myers Squibb: Consulting Fee; Grant/Research Support; Honoraria
Lilly: Consulting Fee; Grant/Research Support
Genentech, Inc.: Consulting Fee; Grant/Research Support; Honoraria
Genmab A/S: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support
Johnson & Johnson: Honoraria
Miltenyi Biotec: Honoraria
Novartis Pharmaceuticals Corporation: Consulting Fee; Grant/Research Support; Honoraria
Pfizer Inc.: Honoraria

Shayna Sarosiek, MD

AstraZeneca Pharmaceuticals LP: Grant/Research Support
ADC Therapeutics: Consulting Fee; Grant/Research Support
Sobi-Swedish Orphan Biovitrum AB: Grant/Research Support

Salyka M. Sengsayadeth, MD

AbbVie, Inc.: Grant/Research Support
Alexion Pharmaceuticals, Inc.: Grant/Research Support
Janssen Pharmaceutical Products, LP: Grant/Research Support

Benjamin Tomlinson, MD

Bristol Myers Squibb: Consulting Fee; Grant/Research Support